Managing Expectations: "We're Still On Target" Says AstraZeneca CEO
Executive Summary
Pascal Soriot says AstraZeneca remains on track to hit its $45bn sales target in 2023 – more or less - but to do that the UK's second biggest drug maker must maintain recent improvements in R&D productivity.
You may also be interested in...
AstraZeneca Links With Alibaba And Tencent In China 'Digital Health' Push
AstraZeneca agreed two new deals with Chinese tech groups Alibaba and Tencent as it tries to expand business in modernizing China, now the UK drug maker's second-largest market after the US.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.
Incyte Plays Down Ruxolitinib Cream Label Worries Following Atopic Dermatitis Approval
Incyte welcomed FDA approval of its ruxolitinib cream, a selective JAK1/JAK2 inhibitor, as a treatment for atopic dermatitis, but criticized the boxed warnings label assigned to it.